NANOPAC 24/30 Trademark

Trademark Overview

On Monday, September 18, 2017, a trademark application was filed for NANOPAC 24/30 with the United States Patent and Trademark Office. The USPTO has given the NANOPAC 24/30 trademark a serial number of 87612006. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, February 22, 2021. This trademark is owned by NanOlogy, LLC. The NANOPAC 24/30 trademark is filed in the Pharmaceutical Products category with the following description:

Active pharmaceutical ingredients, namely, nano-sized particles of paclitaxel sold as a component of pharmaceutical preparations for the prophylaxis and treatment of cancer and cystic lesions by local administration
nanopac 24/30

General Information

Serial Number87612006
Word MarkNANOPAC 24/30
Filing DateMonday, September 18, 2017
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, February 22, 2021
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 21, 2017

Trademark Statements

Goods and ServicesActive pharmaceutical ingredients, namely, nano-sized particles of paclitaxel sold as a component of pharmaceutical preparations for the prophylaxis and treatment of cancer and cystic lesions by local administration

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, September 21, 2017
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameNanOlogy, LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressFort Worth, TX 76107
Party NameNanOlogy, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressFort Worth, TX 76107

Trademark Events

Event DateEvent Description
Monday, February 22, 2021ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, February 22, 2021ABANDONMENT - NO USE STATEMENT FILED
Wednesday, July 22, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, July 21, 2020EXTENSION 5 GRANTED
Tuesday, June 30, 2020EXTENSION 5 FILED
Tuesday, July 21, 2020CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, June 30, 2020TEAS EXTENSION RECEIVED
Friday, January 17, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, January 15, 2020EXTENSION 4 GRANTED
Wednesday, January 15, 2020EXTENSION 4 FILED
Wednesday, January 15, 2020TEAS EXTENSION RECEIVED
Wednesday, July 17, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, July 15, 2019EXTENSION 3 GRANTED
Monday, July 15, 2019EXTENSION 3 FILED
Monday, July 15, 2019TEAS EXTENSION RECEIVED
Thursday, January 17, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, January 15, 2019EXTENSION 2 GRANTED
Tuesday, January 15, 2019EXTENSION 2 FILED
Tuesday, January 15, 2019TEAS EXTENSION RECEIVED
Wednesday, June 20, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, June 18, 2018EXTENSION 1 GRANTED
Monday, June 18, 2018EXTENSION 1 FILED
Monday, June 18, 2018TEAS EXTENSION RECEIVED
Tuesday, January 16, 2018NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, November 21, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, November 21, 2017PUBLISHED FOR OPPOSITION
Wednesday, November 1, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, October 18, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, October 10, 2017ASSIGNED TO EXAMINER
Thursday, September 21, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, September 21, 2017NEW APPLICATION ENTERED IN TRAM

Related Keywords

nanopac pharmaceutical cancer treatment prophylaxis cystic lesions administration local preparations sold